Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIP NASDAQ:OCUL NASDAQ:VERA NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$90.78-0.9%$90.11$52.50▼$99.50$1.99B0.58326,166 shs264,285 shsOCULOcular Therapeutix$11.94+0.3%$12.28$5.78▼$13.85$2.07B1.453.43 million shs4.07 million shsVERAVera Therapeutics$30.53+0.1%$24.23$18.53▼$51.61$1.95B1.231.47 million shs1.00 million shsZVRAZevra Therapeutics$10.82+1.7%$9.41$6.19▼$13.16$597.28M1.492.63 million shs2.01 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals-0.95%+1.85%-7.80%+39.75%+60.02%OCULOcular Therapeutix+0.25%+7.96%-6.43%+8.25%+28.39%VERAVera Therapeutics+0.10%+4.59%+21.73%+28.17%-21.58%ZVRAZevra Therapeutics+1.69%+16.22%+31.79%-13.65%+27.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$90.78-0.9%$90.11$52.50▼$99.50$1.99B0.58326,166 shs264,285 shsOCULOcular Therapeutix$11.94+0.3%$12.28$5.78▼$13.85$2.07B1.453.43 million shs4.07 million shsVERAVera Therapeutics$30.53+0.1%$24.23$18.53▼$51.61$1.95B1.231.47 million shs1.00 million shsZVRAZevra Therapeutics$10.82+1.7%$9.41$6.19▼$13.16$597.28M1.492.63 million shs2.01 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals-0.95%+1.85%-7.80%+39.75%+60.02%OCULOcular Therapeutix+0.25%+7.96%-6.43%+8.25%+28.39%VERAVera Therapeutics+0.10%+4.59%+21.73%+28.17%-21.58%ZVRAZevra Therapeutics+1.69%+16.22%+31.79%-13.65%+27.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 2.90Moderate Buy$99.149.21% UpsideOCULOcular Therapeutix 2.75Moderate Buy$22.6389.49% UpsideVERAVera Therapeutics 2.60Moderate Buy$63.00106.35% UpsideZVRAZevra Therapeutics 2.63Moderate Buy$24.00121.81% UpsideCurrent Analyst Ratings BreakdownLatest ZVRA, ANIP, OCUL, and VERA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/9/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$77.00 ➝ $90.0010/8/2025OCULOcular TherapeutixHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $19.0010/8/2025ANIPANI PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)10/8/2025OCULOcular TherapeutixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VERAVera TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/3/2025OCULOcular TherapeutixPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$21.00 ➝ $31.0010/3/2025OCULOcular TherapeutixRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$17.00 ➝ $24.0010/2/2025OCULOcular TherapeutixZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold10/2/2025OCULOcular TherapeutixChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.0010/1/2025OCULOcular TherapeutixCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform10/1/2025OCULOcular TherapeutixJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$20.00 ➝ $29.00(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M3.21$7.53 per share12.06$19.11 per share4.75OCULOcular Therapeutix$56.66M36.66N/AN/A$2.01 per share5.94VERAVera TherapeuticsN/AN/AN/AN/A$9.08 per shareN/AZVRAZevra Therapeutics$23.61M25.72N/AN/A$0.74 per share14.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals-$18.52M-$0.77N/A21.56N/A-1.37%25.03%8.00%11/14/2025 (Estimated)OCULOcular Therapeutix-$193.51M-$1.28N/AN/AN/A-382.51%-71.92%-49.36%11/13/2025 (Estimated)VERAVera Therapeutics-$152.15M-$3.58N/AN/AN/AN/A-46.70%-39.46%11/6/2025 (Estimated)ZVRAZevra Therapeutics-$105.51M-$0.21N/A54.10N/A4.33%-112.40%-37.67%11/11/2025 (Estimated)Latest ZVRA, ANIP, OCUL, and VERA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025VERAVera Therapeutics-$1.20N/AN/AN/AN/AN/A9/8/2025Q2 2025ANIPANI PharmaceuticalsN/A$1.80N/AN/AN/A$211.37 million8/12/2025Q2 2025ZVRAZevra Therapeutics$1.43-$0.06-$1.49$1.21$22.49 million$25.88 million8/8/2025Q2 2025ANIPANI Pharmaceuticals$1.42$1.80+$0.38$0.36$187.18 million$211.37 million8/5/2025Q2 2025OCULOcular Therapeutix-$0.35-$0.39-$0.04-$0.39$13.12 million$13.46 million8/5/2025Q2 2025VERAVera Therapeutics-$0.82-$1.20-$0.38-$1.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.392.541.96OCULOcular Therapeutix0.2310.1010.02VERAVera Therapeutics0.1617.0317.03ZVRAZevra Therapeutics0.527.857.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%OCULOcular Therapeutix59.21%VERAVera Therapeutics99.21%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals11.10%OCULOcular Therapeutix2.30%VERAVera Therapeutics16.30%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.70 million19.29 millionOptionableOCULOcular Therapeutix230174.00 million169.99 millionOptionableVERAVera Therapeutics4063.82 million53.42 millionOptionableZVRAZevra Therapeutics2056.13 million54.79 millionOptionableZVRA, ANIP, OCUL, and VERA HeadlinesRecent News About These CompaniesZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)October 6, 2025 | globenewswire.comZevra Therapeutics (NASDAQ:ZVRA) Sees Unusually-High Trading Volume - Should You Buy?October 6, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Downgraded to Hold Rating by Wall Street ZenOctober 5, 2025 | americanbankingnews.comZevra Therapeutics (NASDAQ:ZVRA) Rating Lowered to Hold at Wall Street ZenOctober 4, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Shares Gap Down - What's Next?September 30, 2025 | marketbeat.comCan Zevra Therapeutics (ZVRA) Turn Clinical Momentum Into Sustainable Competitive Advantage?September 29, 2025 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSeptember 28, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Upgraded to "Buy" at Wall Street ZenSeptember 26, 2025 | marketbeat.comZevra Therapeutics rises amid takeover speculationSeptember 25, 2025 | msn.comZevra Therapeutics (NASDAQ:ZVRA) Shares Gap Up - Here's WhySeptember 25, 2025 | marketbeat.comZevra Therapeutics Sees Unusually High Options Volume (NASDAQ:ZVRA)September 25, 2025 | marketbeat.comZevra Therapeutics (ZVRA) Soars 10.4%: Is Further Upside Left in the Stock?September 25, 2025 | zacks.comZevra Therapeutics (NASDAQ:ZVRA) Sees Unusually-High Trading Volume - Here's WhySeptember 24, 2025 | marketbeat.comGoldman Sachs Group Inc. Trims Stock Holdings in Zevra Therapeutics, Inc. $ZVRASeptember 21, 2025 | marketbeat.comZevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology ...September 18, 2025 | markets.businessinsider.comZevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)September 18, 2025 | globenewswire.comZevra Therapeutics (NASDAQ:ZVRA) Director Purchases $24,733.25 in StockSeptember 17, 2025 | marketbeat.comZevra Therapeutics (ZVRA) Announces Positive New Data Supporting Foundational Role of MIPLYFFA® for the Treatment of Niemann-Pick Disease Type CSeptember 17, 2025 | insidermonkey.comZevra Therapeutics (NASDAQ:ZVRA) Director Tamara Favorito Purchases 3,175 SharesSeptember 17, 2025 | insidertrades.comA Fresh Look at Zevra Therapeutics (ZVRA) Valuation Following New MIPLYFFA Data ReleaseSeptember 16, 2025 | finance.yahoo.comAlvin Shih Adds To Zevra Therapeutics HoldingSeptember 16, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZVRA, ANIP, OCUL, and VERA Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$90.78 -0.87 (-0.95%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$90.84 +0.06 (+0.07%) As of 04:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Ocular Therapeutix NASDAQ:OCUL$11.94 +0.03 (+0.25%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$12.17 +0.23 (+1.96%) As of 04:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Vera Therapeutics NASDAQ:VERA$30.53 +0.03 (+0.10%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$30.53 0.00 (0.00%) As of 10/9/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.Zevra Therapeutics NASDAQ:ZVRA$10.82 +0.18 (+1.69%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$10.86 +0.04 (+0.42%) As of 04:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
